Modern approaches to the choice of hypoglycemic therapy in patients with type 2 diabetes mellitus: a niche of DPP-4 inhibitors
- Авторлар: Chernikova N.A1, Knyshenko O.A1
-
Мекемелер:
- Russian Medical Academy of Continuous Professional Education
- Шығарылым: Том 27, № 4 (2020)
- Беттер: 33-39
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312542
- DOI: https://doi.org/10.18565/pharmateca.2020.4.33-39
- ID: 312542
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Among 9 classes of antidiabetic drugs used, dipeptidyl peptidase-4 (IDPP-4) inhibitors were firmly established in medical practice about 14 years ago. To date, drugs of this group are confidently prescribed as the first-line therapy for type 2 diabetes mellitus. Features of drugs of this class allow the use of DPP-4 inhibitors in various groups of patients, especially requiring close attention. These include the older age group, patients prone to hypoglycemia, and suffering from end-stage renal disease, when the possibilities for choosing hypo-glicemic therapy are extremely limited. Furthermore, the safety of the use of most drugs of this group in the presence of cardiovascular pathology is also important, and it allows them to be used in the vast majority of patients with type 2 diabetes mellitus.
Негізгі сөздер
Толық мәтін
Авторлар туралы
N. Chernikova
Russian Medical Academy of Continuous Professional Education
Email: nachendoc@yandex.ru
Dr. Sci. (Med.), Associate Professor, Department of Endocrinology
O. Knyshenko
Russian Medical Academy of Continuous Professional Education
Әдебиет тізімі
- IDF Diabetes Atlas - 7th edition. [Cited 2016 Nov 12]. Available from: http://www.diabetesatlas.org
- ВОЗ. URL: https://www.who.int/features/ factfiles/diabetes/ru
- American Diabetes Association. Approaches to glycemic treatment. Diab Care. 2016;39(Suppl. 1):S52-9.
- URL: https://www.rlsnet.ru/tn_indexjd_37571. htm
- Holst J.J., Knop F.K., Vilsb0ll T., et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diab Care. 2011;34(Suppl. 2):S251-57.
- Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008.
- Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18(2):245-58.
- Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl.):S3-18. Doi: 10.1016/j. amjmed.2010.11.002.
- Zhong J, Rao X., Rajagopalan S. An emerging role of dipeptidylpeptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atheroscler. 2013;226(2):305-14. doi: 10.1016/j.atherosclerosis.2012.09.012.
- Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. Doi: http://dx.doi. org/10.1056/NEJMoa1307684
- White W.B., Cannon C.P, Heller S.R., et al.; for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35. doi: 10.1056/NEJMoa1305889.
- Green J.B., Bethel M.A., Armstrong PW., et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42. Doi: 10.1056/ NEJMoa1501352.
- Savarese G., Perrone-Filardi P, DAmore C., et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol. 2015;181:239-44. Doi: http://dx.doi. org/10.1016/j.ijcard.2014.12.017.
- Scirica B.M., Braunwald E., Raz I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI53 randomized trial. Circulation. 2014;130:1579-88. doi: 10.1161/CIRCULATI0NAHA.115.015511.
- Мкртумян А.М., Бирюкова Е.В., Морозова И.А. Эффективность и безопасность ситаглиптина: доказательная база для клинического применения и перспективы. Поликлиника. 2015;1-2:63-70.
- Ma M., Hasegawa Y, Koibuchi N., et al. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc Diabetol. 2015;14:54.
- Zannad F, Cannon C.P, Cushman W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, doubleblind trial. Lancet. 2015;385:2067-76. doi: 10.1016/s0140-6736(14)62225-x.
- Toh S., Hampp C., Reichman M.E., et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other anti-hyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164(11):705-14. Doi: 10.732 6/M15-2568.
- Hippisley-Cox J., Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;12(354):i3477. Doi: https://doi. org/10.1136/bmj.i3477.
- Filion K.B., Azoulay L., Platt R.W., et al., CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145-54. Doi: 10.1056/ NEJMoa1506115.
- Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? lessons from EXAMINE, SAVOR and TECOS. Diab Care. 2016;39(Suppl. 2):S210-18. Doi: https://doi.org/10.2337/dcS15-3009.
- Cooper M.E., Perkovic V, McGill J.B., et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441-49. Doi: 10.1053/j. ajkd.2015.03.024.
- Mosenzon O, leibowitz G, Bhatt D.L., et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diab. Care. Oct 17 pii: dc160621. [Epub ahead of print].
- Roussel R, et al. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diab Obes Metab. 2019;21:781-90. doi: 10.1111/dom.13574.
Қосымша файлдар
